Scholarlink

Background <p>Chronic rhinosinusitis (CRS) is a highly prevalent inflammatory condition of the paranasal sinuses and nasal cavities, which affects 5% to 28% of the general population and can have a profound impact on quality of life.</p> Aim and objectives <p>To evaluate the effectiveness of Tezepelumab during the first year of treatment of Chronic rhinosinusitis with nasal polyps, focusing on improvement in Sino-Nasal Outcome Test.</p> Subjects and methods <p>This systematic review and meta-analysis study contained 4 studies (Laidlaw et al., 2023, Emson et al., 2021, Jacobs et al., 2024 and Lipworth et al., 2025).</p> Result <p>The pooled analysis of the SNOT-22 total score highlighted a significant reduction in scores, indicating improved patient outcomes. The combined effect size showed MD of -9.31, with CI from -15.17 to -3.46. This suggests a notable decrease in SNOT-22 scores, reflecting better symptom management. The overall effect yielded a Z value of 2.39, confirming the significant reduction in SNOT-22 scores.</p> Conclusion <p>This meta-analysis demonstrates that Tezepelumab significantly reduces annualized asthma exacerbation rates (AAER) and improves asthma control, as evidenced by the substantial reduction in Asthma Control Questionnaire (ACQ -6 scores). Additionally, there is a notable improvement in symptom burden, reflected by decreased SNOT-22 scores, indicating enhanced quality of life. Although no significant change was observed in pre-bronchodilator (FEV1), suggesting limited effect on baseline lung function, the overall findings support the effectiveness of Tezepelumab in improving clinical outcomes in asthma. Furthermore, evidence from recent clinical trials shows that Tezepelumab is also effective in the treatment of chronic rhino sinusitis with nasal polyps (CRSwNP). These results reinforce Tezepelumab’s role as a promising therapeutic option in the management of both severe asthma and chronic rhino sinusitis with nasal polyps (CRSwNP), although further research is warranted to better understand variability across patient populations and optimize treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Is Tezepelumab effective in treatment of chronic rhinosinusitis with nasal Polyps?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月11日

查看全文
  • Mohamed M. Thabit,
  • Hesham A. El-Sersy,
  • Tarek A. Hamdy,
  • Mohammed Aleem

摘要

Background

Chronic rhinosinusitis (CRS) is a highly prevalent inflammatory condition of the paranasal sinuses and nasal cavities, which affects 5% to 28% of the general population and can have a profound impact on quality of life.

Aim and objectives

To evaluate the effectiveness of Tezepelumab during the first year of treatment of Chronic rhinosinusitis with nasal polyps, focusing on improvement in Sino-Nasal Outcome Test.

Subjects and methods

This systematic review and meta-analysis study contained 4 studies (Laidlaw et al., 2023, Emson et al., 2021, Jacobs et al., 2024 and Lipworth et al., 2025).

Result

The pooled analysis of the SNOT-22 total score highlighted a significant reduction in scores, indicating improved patient outcomes. The combined effect size showed MD of -9.31, with CI from -15.17 to -3.46. This suggests a notable decrease in SNOT-22 scores, reflecting better symptom management. The overall effect yielded a Z value of 2.39, confirming the significant reduction in SNOT-22 scores.

Conclusion

This meta-analysis demonstrates that Tezepelumab significantly reduces annualized asthma exacerbation rates (AAER) and improves asthma control, as evidenced by the substantial reduction in Asthma Control Questionnaire (ACQ -6 scores). Additionally, there is a notable improvement in symptom burden, reflected by decreased SNOT-22 scores, indicating enhanced quality of life. Although no significant change was observed in pre-bronchodilator (FEV1), suggesting limited effect on baseline lung function, the overall findings support the effectiveness of Tezepelumab in improving clinical outcomes in asthma. Furthermore, evidence from recent clinical trials shows that Tezepelumab is also effective in the treatment of chronic rhino sinusitis with nasal polyps (CRSwNP). These results reinforce Tezepelumab’s role as a promising therapeutic option in the management of both severe asthma and chronic rhino sinusitis with nasal polyps (CRSwNP), although further research is warranted to better understand variability across patient populations and optimize treatment strategies.